Catalog No.
DHE85401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
C-C CKR-5, CC-CKR-5, CMKBR5, HIV-1 fusion coreceptor, CHEMR13, CCR5, C-C chemokine receptor type 5, CD195, CCR-5
Concentration
4.27 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P51681
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
HuPRO-140, PA-14, PRO-140, CAS: 674782-26-4
Clone ID
Leronlimab
Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab, PMID: 33079180
Antibodies to watch in 2020, PMID: 31847708
Antibodies to watch in 2021, PMID: 33459118
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications, PMID: 32599589
Antibodies to watch in 2019, PMID: 30516432
Clinical significance of chemokine receptor antagonists, PMID: 31903790
Advances in Long-Acting Agents for the Treatment of HIV Infection, PMID: 32180205
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy, PMID: 33485378
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology, PMID: 31292161
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme, PMID: 31747383
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19, PMID: 32511656
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14, PMID: 33186704
Antibody-based strategies in HIV therapy, PMID: 33045349
A review of antibody-based therapeutics targeting G protein-coupled receptors: an update, PMID: 32264722
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab, PMID: 33521616
Anti-HIV-1 Antibodies: An Update, PMID: 32152957
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab, PMID: 33778462
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission, PMID: 34099693
New drugs, PMID: 18953271
The return of PRO 140, a CCR5-directed mAb, PMID: 29708899
PRO 140--a novel CCR5 co-receptor inhibitor, PMID: 19807678
Healthcare resource use among solid organ transplant recipients hospitalized with COVID-19, PMID: 33349940
[Functional diversity of myosin motors], PMID: 12166062
Monoclonal CCR5 antibody for treatment of people with HIV infection, PMID: 21154397
Biology of CCR5 and its role in HIV infection and treatment, PMID: 16905787
Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels, PMID: 33912796
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer, PMID: 32130619
Vascular Patterning as Integrative Readout of Complex Molecular and Physiological Signaling by VESsel GENeration Analysis, PMID: 33839725
Fear acquisition and extinction deficits in amnestic mild cognitive impairment and early Alzheimer's disease, PMID: 31843256
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection, PMID: 25063928
Initial results for PRO 140, PMID: 16283839
Trials begin for PRO 140, PMID: 15635750
Entry inhibitor combination shows promise, PMID: 11228623
Phase 2 clinical trials started on PRO 140, PMID: 18273941
Anti-HIV agents. PRO 140--a receptor antibody for HIV, PMID: 18041151
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice, PMID: 29128556
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection, PMID: 29676212
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody, PMID: 20377413
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults, PMID: 20660677
A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src, PMID: 12649175
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults, PMID: 18771406
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140), PMID: 16890780
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1, PMID: 17005807
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C, PMID: 12634405
For research use only. Not for human or drug use.
